logo

Lipocine Inc (LPCN)



Trade LPCN now with
  Date
  Headline
1/11/2018 10:33:06 AM Canaccord Is Increasing Lipocine Inc (LPCN) FY18 Estimate To -1.05 From -1.10
1/11/2018 10:24:34 AM Canaccord Lowers Lipocine Inc (LPCN) To Hold From Buy With $2 Down From $11 Price Target
11/17/2017 8:06:47 AM Lipocine Says FDA Extended Review Period For NDA For TLANDO
11/8/2017 8:12:56 AM Lipocine Q3 Net Loss $4.7 Mln Or $0.22/shr Vs. Loss Of $3.2 Mln Or $0.18/shr Prior Year
9/21/2017 8:04:27 AM Lipocine Reports Motions Decision By USPTO In Interference Against Clarus
9/20/2017 8:03:18 AM Lipocine Announces FDA Advisory Committee Meeting For TLANDO
8/14/2017 8:14:28 AM Lipocine Announces FDA Acknowledgement Of TLANDO NDA Resubmission; PDUFA Goal Date, February 8, 2018
8/9/2017 8:06:06 AM Lipocine Resubmits NDA For Oral Testosterone Product Candidate, LPCN 1021, For Treatment Of Hypogonadism
6/26/2017 8:04:37 AM Lipocine Reports Submission Of SPA On LPCN 1107, Oral Alternative For The Prevention Of Preterm Birth
5/8/2017 8:09:32 AM Lipocine Q1 Net Loss $4.9 Mln Or $0.26/Shr Vs Net Loss $7.0 Mln Or $0.38/Shr Last Year
1/9/2017 7:11:29 AM Lipocine Says Gets FDA Guidance On Phase 3 Program For LPCN 1107